<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160432</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5703433</org_study_id>
    <secondary_id>2010-021814-43</secondary_id>
    <nct_id>NCT01160432</nct_id>
  </id_info>
  <brief_title>Naloxone Methadone Combination (NAMEKO)</brief_title>
  <acronym>NAMEKO</acronym>
  <official_title>The Safety and Tolerability of Methadone/Naloxone Combination in Opioid Substitution Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine the tolerability and abuse potential of the diluted
      methadone solution (5 mg/ml → 2 mg/ml) in combination with naloxone in opioid substitution
      treatment.

      Study hypothesis: Treatment with this diluted combination product is safer than with
      methadone alone (5 mg/ml) and combination product does not precipitate withdrawal symptoms in
      opioid dependent patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Withdrawal symptoms (Clinical Opioid Withdrawal Scale COWS, Subjective Opiate Withdrawal Scale SOWS)</measure>
    <time_frame>1/2 hours after the first intake of medicine every week</time_frame>
    <description>COWS is completed by the nurse and SOWS by the patient. Withdrawal symptoms are estimated every week after the intake of new product (blinded).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effectiveness of treatment (Treatment Outcomes Profile TOP)</measure>
    <time_frame>Before study begins, after 4 week study period and 4 weeks after the end of the clinical phase.</time_frame>
    <description>Structured interview designed to measure the effectiveness and outcomes of opioid substitution treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>Methadone naloxone combination product 2/0,04 mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone 2 mg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone, naloxone</intervention_name>
    <description>Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient`s individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week`s periods for four weeks.</description>
    <arm_group_label>Methadone naloxone combination product 2/0,04 mg/ml</arm_group_label>
    <arm_group_label>Methadone 2 mg/ml</arm_group_label>
    <other_name>Methadone Martindale Pharma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  opioid dependence

          -  methadone treatment

          -  no changes in methadone dose during the last 10 days

          -  good treatment compliance according to doctor

          -  normal ALAT and AFOS values (increased if double the normal level)

        Exclusion Criteria:

          -  severe renal or hepatic failure

          -  acute psychosis

          -  age under 18

          -  pregnancy

          -  legal incompetence

          -  severe somatic disease

          -  chaotic situation in life

          -  medication or disease which is contraindication to study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Tacke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kuopio University Hospital, University of Eastern Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuopio University Hospital</investigator_affiliation>
    <investigator_full_name>Ulrich Tacke</investigator_full_name>
    <investigator_title>MD, PhD, docent</investigator_title>
  </responsible_party>
  <keyword>opiate dependence</keyword>
  <keyword>methadone</keyword>
  <keyword>naloxone</keyword>
  <keyword>withdrawal symptom</keyword>
  <keyword>substitution treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

